Cariprazine – Mechanism of Action | Psychopharmacology | Clinical Application
DRUG DESCRIPTION AND STRUCTURE
Cariprazine (Vraylar, Reagila) is an atypical antipsychotic approved in September 2015 to treat schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy. [McCormack 2015]
Cariprazine, or N-alkylpiperazine, is an organic compound consisting of a phenyl group bound to a piperazine skeleton. [Citrome 2013]
Fagiolini, A., Alcalá, J. Á., Aubel, T., Bienkiewicz, W., Bogren, M. M. K., Gago, J., … & Vernaleken, I. B. (2020). Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. Annals of General Psychiatry, 19(1), 1-11.